Pharmazie最新文献

{"title":"TIM-1 attenuates airway mucus hypersecretion and inflammation induced by cigarette smoke via the PI3K/Akt signaling pathway.","authors":"Qiang Li, Hang Shang, Xiangshun Li, Guangrun Wu, Lixia Qiang","doi":"10.1691/ph.2024.4612","DOIUrl":"10.1691/ph.2024.4612","url":null,"abstract":"<p><p>Cigarette smoke extract (CSE)-induced airway mucus hypersecretion and inflammation are prominent features of chronic obstructive pulmonary disease (COPD). As a factor associated with inflammation regulation, T cell immunoglobulin and mucin domain-1 (TIM-1) is found to be involved in various inflammatory disorders such as asthma and COPD. In this study, the GEO database provides two human COPD gene expression datasets (GSE67472, n = 62) along with the relevant controls (n = 43) for differentially expressed gene (DEG) analyses. Candidate biomarkers are identified, and the discriminatory ability is determined using the area under the receiver operating characteristic curve (AUC) values. Furthermore, a COPD mouse model is established using CSE to validate that anti-TIM-1 can attenuate airway mucus hypersecretion and inflammation via the PI3K/Akt signaling pathway in COPD. Anti-TIM-1 antibody pretreatment significantly suppresses mucin secretion, inflammatory cell infiltration, and inflammatory cytokine release in mouse lungs induced by CSE and also suppresses CSE-induced expression of MUC5AC. Western blot shows that the anti-TIM-1 antibody attenuates the activation of p-Akt in airway mucus hypersecretion mice induced by CSE. This study highlights the protective effect of the TIM-1 antibody on CSE-related airway mucus hypersecretion and inflammation, in which PI3K/AKT may be involved. These findings suggest that TIM-1 could be a potential therapeutic target for airway mucus hypersecretion.</p>","PeriodicalId":20145,"journal":{"name":"Pharmazie","volume":"79 10","pages":"220-227"},"PeriodicalIF":1.5,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143053230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quantification of ivermectin in veterinary products consumed off-label as a treatment for COVID-19.","authors":"C Wentzel, N Gernandt, M Gerber, F Van Der Kooy","doi":"10.1691/ph.2024.4035","DOIUrl":"10.1691/ph.2024.4035","url":null,"abstract":"<p><p>The COVID-19 pandemic caused global pandemonium, and due to an unprecedented global response, the popularity and use of (veterinary) ivermectin, amongst many other conceivable 'treatments', experienced a meteoric rise. Ivermectin is a macrocyclic lactone compound belonging to the avermectin drug class and is a registered medicine in many countries, although the most common use is as veterinary medicine. In this study, a fast HPLC method was developed and validated for the quantification of ivermectin in veterinary products that were used off-label by a substantial number of people during COVID-19. Locally used veterinary products were collected as well as commercial products acquired and were tested using the newly developed method. The ivermectin content was compared to the products' label claims and it was found that all products tested contained ivermectin within acceptable limits. However, the use of veterinary products is strongly discouraged due to high dosages and administration regimens that were tested in animals and can lead to serious adverse events in humans. The presence of untested excipients and secondary actives, such as clorsulon, which can cause unknown (long-term) health impacts in humans, further adds credence to this warning.</p>","PeriodicalId":20145,"journal":{"name":"Pharmazie","volume":"79 10","pages":"216-219"},"PeriodicalIF":1.5,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143053224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pilot of a joint bed-side teaching course for medical and pharmacy university students.","authors":"T Stegmann, M P Neininger, U Laufs, T Bertsche","doi":"10.1691/ph.2024.4598","DOIUrl":"10.1691/ph.2024.4598","url":null,"abstract":"<p><p><i>Background and aim</i>: Interprofessional education of medical and pharmacy students may improve competence-based university teaching. <i>Investigations</i>: We developed a joint bed-side teaching to improve patient-related competencies in identifying drug-related problems in hospitalized patients at a university cardiology department. Students were randomly allocated in mixed teams of medical and pharmacy students (1:3). The concept consisted of four parts: (i) kick-off session (day 1), (ii) file analysis and bed-side patient interview (day 2), (iii) medication analysis (free time management), and (iv) presentation of the acquired results (day 3). Expectations and competencies, predefined in 10 categories and 10 assessment levels (0-none to 10-maximum), were evaluated before and after the course (degree of fulfillment of the expectations reported after the course). <i>Results</i>: Overall, 12 students participated, eight of whom were female. Median age was 23 years (Q25/Q75: 22/24). The median time at university was 8 semesters (Q25/Q75: 7/9). The competencies were assessed by the students before and after the course in the following categories: Competencies in \"Treatment of diseases\" (median rating before/after the course: 6/7; n.s.), \"Diagnostics of diseases\" (4.5/5; n.s.), \"Future physician-pharmacist cooperation\" (6/8; p=0.005), \"Interaction with patients\" (6.5/7; n.s.), \"Cardiology\" (5/7; p=0.012), \"Interprofessional student communication\" (6.5/9; p=0.005), \"Dealing with patient-oriented questions\" (6.5/8; n.s.), \"Future professional life\" (5/7.5; p=0.012), \"Practical problem solving\" (6/7; p=0.027), \"Scientific work\" (6/7.5; n.s.). Expectations before the course were highest (median of 10) in the categories \"Future physician-pharmacist cooperation\", \"Dealing with patient-oriented questions\", \"Future professional life\", and \"Practical problem solving\". The highest levels of expectation fulfilment were reported after the course for the categories \"Future physician-pharmacist cooperation\" and \"Interprofessional student-communication\". In the free text, interprofessional collaboration was frequently mentioned as a particularly positive aspect of the course. <i>Conclusions</i>: A pilot joint bed-side teaching course for medical and pharmacy students was feasible and an early interprofessional collaboration during medical and pharmacy studies may improve several competencies particularily regarding competencies in physician-pharmacist cooperation and in interprofessional student communication.</p>","PeriodicalId":20145,"journal":{"name":"Pharmazie","volume":"79 10","pages":"240-245"},"PeriodicalIF":1.5,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143053221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Methylenetetrahydrofolate reductase (<i>MTHFR</i>) C677T and A1298C polymorphisms are associated with major depressive disorder in the Saudi patients attending Erada complex for mental health and Erada services - Jeddah, Saudi Arabia.","authors":"A M Bagher, M F Alkhaldi, J A Somaily, D A Altheyab, M A Khafaji, R F Awad, B G Eid, L S Binmahfouz","doi":"10.1691/ph.2024.4601","DOIUrl":"10.1691/ph.2024.4601","url":null,"abstract":"<p><p><i>Background</i>: Major Depressive Disorder (MDD) is a prevalent and debilitating mental disorder that has been linked to hyperhomocysteinemia and folate deficiency. These conditions are influenced by the methylenetetrahydrofolate reductase (<i>MTHFR</i>) gene, which plays a crucial role in converting homocysteine to methionine and is essential for folate metabolism and neurotransmitter synthesis, including serotonin. <i>Study aim</i>: This study explored the association between <i>MTHFR C677T</i> and <i>A1298C</i> polymorphisms among Saudi MDD patients attending the Erada Complex for Mental Health and Erada Services outpatient clinic in Jeddah, Saudi Arabia. <i>Methods</i>: The study involved 87 MDD patients and 87 control subjects. Saliva samples were collected, and genomic DNA was extracted. Polymerase chain reaction-restriction fragment length polymorphism was used to detect <i>MTHFR</i> gene polymorphisms. <i>Results</i>: A significant difference was observed in the distribution of genotype frequencies for <i>MTHFR C677T</i> and <i>A1298C</i> polymorphisms between MDD patients and controls in the Saudi cohort (<i>C677T</i>: <i>P</i> = 0.001; <i>A1298C</i>: <i>P</i> = 0.01) Risk analysis indicated that individuals with the mutant TT genotype of the <i>C677T</i> polymorphism (Odd Ratio (OR) = 6.80, CI 95% = 1.47-31.36, <i>P</i> = 0.01) and the mutant CC genotype of the <i>A1298C</i> polymorphism (OR = 2.64, CI 95% = 1.36-5.13, P = 0.004) are more common in MDD patients, suggesting a higher risk for depression. Gender-specific analyses showed that the <i>MTHFR C677T</i> TT genotype significantly increases the risk of MDD in males compared to females. <i>Conclusion</i>: These findings underscore the significant impact of genetic factors, particularly the association of <i>MTHFR</i> polymorphisms with MDD. The results highlight the importance of personalized treatment approaches considering individual genetic profiles.</p>","PeriodicalId":20145,"journal":{"name":"Pharmazie","volume":"79 10","pages":"228-232"},"PeriodicalIF":1.5,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143053218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of progression-free and overall survival in ovarian cancer: Bevacizumab treatment outcomes using historical cohort.","authors":"I Conic, B Nedovic, R Zivadinovic, R Zivadinovic, A Petric, S Stojnev, I Petkovic, D Krtinic, M Radic","doi":"10.1691/ph.2024.4570","DOIUrl":"https://doi.org/10.1691/ph.2024.4570","url":null,"abstract":"<p><p><i>Background:</i> The incorporation of bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF), has redefined therapeutic strategies for advanced ovarian cancer. This study evaluates the efficacy of bevacizumab combined with standard chemotherapy by comparing progression-free survival (PFS) and overall survival (OS) outcomes with a historical cohort of patients treated with standard chemotherapy alone. <i>Methods:</i> We conducted an analysis of 71 patients with advanced epithelial ovarian cancer treated at the University Clinical Center in Niš, Serbia, from April 2017 to March 2023. All patients received standard chemotherapy paired with bevacizumab and were monitored for progression-free survival (PFS) and overall survival (OS) using Kaplan-Meier estimates. Subgroup analyses were performed based on age, ECOG performance status, presence of metastases, and pleural effusion. Additionally, a historical cohort of 30 patients treated with standard chemotherapy alone was used for comparison, and Cox regression analysis was conducted to identify factors influencing treatment outcomes. <i>Results:</i> The study findings indicate significant improvements in median PFS (20 months vs. 15 months) and OS (58 months vs. an undetermined upper limit) compared to the historical cohort. Subgroup analysis of the bevacizumab-treated group revealed that younger patients (<65 years) and those without metastases or pleural effusion exhibited notably better survival outcomes. The hazard ratio for PFS in patients younger than 65 was 0.65 (95% CI: 0.45-0.93), suggesting a substantial reduction in disease progression risk compared to older patients. <i>Conclusion:</i> Bevacizumab, when used alongside standard chemotherapy, significantly extends both PFS and OS in patients with advanced ovarian cancer. These benefits are particularly pronounced in younger patients. The results underscore the necessity of integrating bevacizumab into the treatment regimen for advanced ovarian cancer, advocating for tailored therapeutic strategies based on individual risk profiles and clinical characteristics. This study reinforces the pivotal role of bevacizumab in enhancing the current ovarian cancer treatment landscape and highlights the potential for further personalizing oncological care.</p>","PeriodicalId":20145,"journal":{"name":"Pharmazie","volume":"79 9","pages":"195-201"},"PeriodicalIF":1.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142472455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of pharmacotherapeutic analgesic response and safety profile of tapentadol with other opioids.","authors":"D Krtinic, G N Rankovic, A Cvetanovic, I Conic, M Todorovic Mitic, M Radic, A Lucic Prokin, M Cevrljakovic","doi":"10.1691/ph.2024.4591","DOIUrl":"https://doi.org/10.1691/ph.2024.4591","url":null,"abstract":"<p><p>Tapentadol is a unique opioid analgesic due to its dual mechanism of action. Compared to other opioids with a classical mechanism of action, its analgesic potential is not far behind them, and its advantages are: a better safety profile in terms of a lower potential for drug-drug interactions and a lower potential for causing adverse events, and it is safe to use in sensitive populations. Tapentadol in the form of a immediate release formulation is an adequate drug of choice for achieving a pharmacotherapeutic analgesic response in acute pain conditions, while in the form of a extended release formulation it is an adequate pharmacotherapeutic analgesic solution for chronic pain syndromes of various etiology. Due to the specificity of the mechanism of action, tapentadol adequately relieves both pain components - nociceptive and neuropathic, and has an indication area for mixed pain syndrome as well. Based on this, the need for the use of co-analgesics is reduced, and thus the incidence of possible interactions and adverse events is reduced.</p>","PeriodicalId":20145,"journal":{"name":"Pharmazie","volume":"79 9","pages":"179-183"},"PeriodicalIF":1.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142472456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cross-reactivity of triptans and sulfonamide antibiotics - a clinically relevant question?","authors":"A Kärcher, M Schubert-Zsilavecz, C Gaul","doi":"10.1691/ph.2024.4600","DOIUrl":"https://doi.org/10.1691/ph.2024.4600","url":null,"abstract":"<p><p>After repeated inquiries from patients whether sulfonamide antibiotic allergy should be considered in the context of taking a triptan, we present here the pharmaceutical background, the chemical structure of triptans, and the clinical relevance in a narrative review. In fact, evidence-based cross-reactivity referring to the well-known allergic reaction of sulfonamide antibiotics has not been described so far.</p>","PeriodicalId":20145,"journal":{"name":"Pharmazie","volume":"79 9","pages":"184-186"},"PeriodicalIF":1.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142472457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potential roles for eNOS and NrF₂ /HO-1 signaling in the ameliorative effect of lixisenatide on diabetes-induced kidney injury in rats and its amplification by ticagrelor co-administration.","authors":"M Sleem, E M Aboubakr, W R Mohamed, A M Khalil, B A S Messiha, A Taye","doi":"10.1691/ph.2024.4566","DOIUrl":"https://doi.org/10.1691/ph.2024.4566","url":null,"abstract":"<p><p>Antioxidant and anti-inflammatory effects of lixisenatide (LX) and ticagrelor (TC) have been previously identified in type 2 diabetes mellitus (T2DM). Diabetic nephropathy is one of the major complications of T2DM. In the current study, we examined the potential protective effects of LX and TC on experimentally induced diabetic nephropathy in T2DM rats and their possible molecular mechanisms. To examine this possibility, rats were fed a high-fat diet (HFD) for 12 weeks, followed by a single injection of 35 mg/kg streptozotocin (STZ) to induce T2DM. 10 μg/kg LX and 25 mg/kg TC were given alone or in combination to T2DM rats for 4 weeks. The kidney examination of T2DM rats showed clear deterioration. T2DM rats exhibited significantly higher body weight, blood glucose, hemostatic model assessment for insulin resistance (HOMA-IR), blood urea nitrogen (BUN), serum creatinine, kidney reactive oxygen species (ROS), nuclear factor-κ B (NF-κ B), and transforming growth factor-β (TGF-β ), and significantly lower serum insulin, urine creatinine, creatinine clearance (CRCL), kidney superoxide dismutase (SOD), glutathione reduced (GSH), nuclear factor erythroid 2 (NrF₂ ), heme oxygenase-1 (HO-1), and endothelial nitric oxide synthase (eNOS) when compared to control rats. Single treatment with LX or TC showed obvious ameliorative effects on kidney complications in T2DM rats, with more ameliorative effects with the combined administration of both drugs. Conclusion: Our investigation found that both LX and TC could significantly ameliorate the development of diabetic nephropathy via stimulating NrF₂ /HO-1 antioxidant pathway in addition to increasing eNOS and decreasing NF-κ B renal tissue concentrations, and these effects were markedly augmented by their combined administration.</p>","PeriodicalId":20145,"journal":{"name":"Pharmazie","volume":"79 9","pages":"187-194"},"PeriodicalIF":1.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142472460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of medication reconciliation and medication reviews on the incidence of preventable adverse drug reactions during hospitalization of elderly patients. A randomized controlled trial.","authors":"K Schmitz, R Lenssen, S Wied, A Laven, D Berning, C Thomeczek, J Brokmann, U Jaehde, A Eisert","doi":"10.1691/ph.2024.4540","DOIUrl":"10.1691/ph.2024.4540","url":null,"abstract":"<p><p><i>Background</i>: Of all adverse drug reactions, 35-45% are due to medication errors and would therefore be preventable. Thus, it is essential to implement effective strategies to prevent medication errors. However, it remains unclear whether medication reviews provide an additional benefit compared to medication reconciliation regarding medication safety. <i>Aim</i>: The present study aimed to evaluate whether medication reconciliation and medication reviews affect the incidence of preventable adverse drug reactions in elderly patients. <i>Method</i>: Non-elective patients 65 years and above admitted to the hospital, taking at least one high-risk drug, were eligible for participation in a three-armed randomized controlled trial. One group went through the medication reconciliation process, a second group received a comprehensive medication review, including medication reconciliation, and the third group did not receive any pharmaceutical intervention (control group). The incidence of preventable adverse drug reactions during hospitalization was set as the primary endpoint. The severity of the preventable adverse drug reactions and the number and clinical relevance of drug-related problems and discrepancies were defined as secondary endpoints. <i>Results</i>: In 207 patients, 74 preventable adverse drug reactions were detected. Neither medication reconciliation nor medication reviews showed a significant impact on the incidence of preventable adverse drug reactions compared to the control group. However, medication reviews significantly reduced the severity of preventable adverse drug reactions (p=0.017). <i>Conclusion</i>: The current study results suggest that medication reviews may have an impact on a clinically relevant outcome by reducing the severity of preventable adverse drug reactions. A significant impact of medication reconciliation on clinically relevant outcomes could not be demonstrated. Based on the results of this study, when deciding on a pharmaceutical intervention comprehensive medication reviews should be preferred over sole medication reconciliation whenever possible.</p>","PeriodicalId":20145,"journal":{"name":"Pharmazie","volume":"79 9","pages":"209-214"},"PeriodicalIF":1.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142472458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potential effects of attention deficit hyperactivity disorder medication on body height and body weight in a longitudinal pediatric cohort study, the LIFE Child study.","authors":"M Herzig, V C Klaus, A Bertsche, C Hilbert, W Kiess, T Bertsche, M P Neininger","doi":"10.1691/ph.2024.4551","DOIUrl":"https://doi.org/10.1691/ph.2024.4551","url":null,"abstract":"<p><p><i>Purpose:</i> To investigate the potential impact of drugs for the treatment of attention deficit hyperactivity disorder (ADHD) on body weight and height in children and adolescents from the LIFE ('Leipzig Research Centre for Civilization Diseases', Leipzig, Germany) Child cohort. <i>Methods:</i> We included 2,115 participants aged ≥6 to <18.25 years who attended the LIFE study center between 2011 and 2020 in our analysis, of whom 48 used ADHD drugs. Anthropometric and medication data from baseline to the third follow-up visit were available for 659 participants. Body height and body weight measurements were subsequently converted to z-scores. A repeated measures analysis of variance (ANOVA) was performed on the z-scores of both ADHD drug users and non-users to determine potential trends in body weight and body height from baseline to the 3 rd annual follow-up. <i>Results:</i> At the last visit with ADHD drug use of the 48 ADHD drug users, 40% (19/48) of the children and adolescents were below the 25 th reference percentile for weight. Z-scores for body height declined from baseline to the 3^rd annual follow-up in individuals who used ADHD drugs (n=10; Difference_means =-0.310; p=0.002) compared to non-users (n=649; Difference_means =0.102; p<0.001). Body weight also decreased from baseline to 3^rd follow-up in the ADHD drug group (n=10; Difference_means =-0.473; p<0.001) compared to the non-user group (n=649; Difference_means =0.015; p=0.161). <i>Conclusion:</i> We observed a potential tendency towards lower Z-scores for body height and body weight in individuals taking ADHD medication for an extended period compared to the corresponding age- and sex-matched populations.</p>","PeriodicalId":20145,"journal":{"name":"Pharmazie","volume":"79 9","pages":"202-208"},"PeriodicalIF":1.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142472459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}